Abiraterone Acetate: CYP17 Inhibitor Workflows in Prostat...

2025-10-18

Abiraterone acetate, a potent CYP17 inhibitor and 3β-acetate prodrug of abiraterone, transforms experimental workflows for castration-resistant prostate cancer by enabling precise interrogation of androgen biosynthesis and steroidogenesis. This article details applied protocols, troubleshooting strategies, and advanced use-cases, leveraging high-impact patient-derived 3D spheroid models to set new standards in prostate cancer research.